ANDA 72163, held by Heritage Pharma. Maprotiline Hydrochloride.
As of Nov 16, 2026, ANDA 72163 (Maprotiline Hydrochloride), held by Heritage Pharma, was first approved by FDA on Jun 1, 1988, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Maprotiline Hydrochloride50MG · tablet;oral | Maprotiline Hydrochloride | Discontinued |
| Jul 17, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 7, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Nov 10, 1999 | Supplement 6Manufacturing | Approved | None posted |
| Aug 26, 1998 | Supplement 5Labeling | Approved | None posted |
| Jun 4, 1992 | Supplement 4Labeling | Approved | None posted |
| May 20, 1992 | Supplement 3Labeling | Approved | None posted |
| Nov 29, 1990 | Supplement 2Labeling | Approved | None posted |
| Jun 1, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters